<DOC>
	<DOCNO>NCT02494882</DOCNO>
	<brief_summary>The purpose study test safety new combination three oral drug Ph+ ALL . These drug dexamethasone , dasatinib , ruxolitinib . All three drug study human . This phase I study ruxolitinib dose start low first patient together dexamethasone plus dasatinib . If dose cause bad side effect , ruxolitinib dose slowly make high new patient take part study . This help investigator find right dose ruxolitinib give together dexamethasone dasatinib use future study</brief_summary>
	<brief_title>Adding Ruxolitinib Combination Dasatinib Plus Dexamethasone Remission Induction Therapy Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years Older</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patient able give inform consent . Patients &gt; /= 18 year follow disease eligible Newly diagnose Ph+ ALL , previously untreated , except allowance Previously receive HpyerCVAD cycle 1A+/ cycle 1B Previously receive Induction Phase 1 +/ Induction Phase II BFMmodeled ( Pediatric PediatricInspired ) ALL regimen Previously receive representative ( modified HyperCVAD , BFM , AMLlike ) ALL induction course , include ABL TKI plus corticosteroid . If patient receive prior therapy , may enrol , regardless remission status . Relapsed PH+ ALL , prior exposure dasatinib without know ABL kinase mutation predited resistant dasatibin ( e.g . L248R , L248V , Q252H , E255K , V299L , T315A , T315I , F317C , F317L , F317S , F317V ) Relapsed refractory Phlike ALL without prior exposure dasatibin mutation rearrangement gene confer sensitivity dasatibin ( ABL , CSF1R , PDGFRB ) ruxolitinib ( CRLF2 , JAK3 , EPOR , TSLP ) Newly diagnose relapse CML lymphoid blast crisis Confirmation Philadelphia chromosome positivity cytogenetics ( karyotype/FISH ) and/or molecular test ( BCRABL1 transcript ) Acceptable endorgan function , except document exclusion organ function compromise due ALL ECOG performance status â‰¤ 2 Men woman childbearing potential must willing practice effective method birth control treatment least 4 month follow treatment study Phnegative ALL Patients dominant leukemic clone bearing document bcrabl mutation enable bcrabl TKI resistance diagnosis Mature Bcell ( Burkitt 's ) ALL Serum creatinine &gt; 1.5x ULN calculate creatinine clearance , base 24hour urine collection , &lt; 30 mL/minunless relate ALL/tumor lysis syndrome able correct Direct Bilirubin &gt; 2x ULN ; AST/ALT &gt; 10x ULN , unless relate ALL liver infiltration . Pregnant woman woman breastfeed Patients HIV , Hepatitis B , Hepatitis C Pretreatment QTcF &gt; 480 msec A `` washout '' period least 14 day last previous cytotoxic chemotherapy require prior start treatment protocol . No `` washout '' period require previous bcrabl TKI therapy give aforementioned previous chemotherapy cycle . Hydroxyurea corticosteroid may give bridge therapy 24 hour prior initiate protocol treatment . Active malignancy require treatment ALL within two year prior start treatment , exception basal cell squamous cell carcinoma skin , carcinoma situ cervix , localized prostate cancer , DCIS LCIS breast Active , uncontrolled infection , concurrent disease , medical condition deem interfere conduct study judge investigator Unable tolerate antiviral anti Pneumocystis jirovecii prophylaxis prephase remission induction therapy Unable tolerate gastrointestinal prophylaxis therapy sucralfate prephase remission induction therapy . Or severe preexist GI disorder require PPI H2 receptor antagonist therapy uninterrupted</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Ruxolitinib</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>14-272</keyword>
</DOC>